This risk factor clause is meant for use in a public company's periodic disclosure, such as a Form 10-K, or a registration statement, such as a Form S-1, to disclose risks commonly faced by companies operating in the life sciences industry. This clause contains practical guidance and drafting notes. Life Science companies face particular risks relating to the long, difficult, and expensive process of running pre-clinical studies and clinical trials prior to the commercialization of their products and treatments. The following risk factors disclose common risks relating to product development and commercialization. You should adapt the language in them to the company, its products, the relevant stage in the preclinical or clinical trial process, applicable regulators, and other circumstances. For information on drafting risk factors, see Risk Factor Drafting for a Registration Statement and Top 10 Practice Tips: Risk Factors. For more information on representing life science companies, ...